---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041293"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:17:20.268395+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Femasys receives second $500k FemBloc order from Kebomed for Europe

## Summary
- Order valued at ~$500k for commercial launch of FemBloc in France and Benelux region.
- Kebomed, a leading distributor, placed the order following Femasys' recent entry into Spain.
- FemBloc is a non-surgical permanent contraceptive using a patented polymer to occlude fallopian tubes.
- CEO Kathy Lee-Sepsick cited strategic partnerships driving international expansion and shareholder value.
- No anesthesia, incisions, or recovery time required; addresses unmet need in reproductive health.

## SEC filing metadata
- accession: 0001140361-25-041293
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036125041293/0001140361-25-041293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036125041293/ef20058658_form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041293
- JSON: https://secwatch.observer/filing/0001140361-25-041293.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.